CKLF-CMTM1

Across TCGA pan-cancer cohorts, CKLF-CMTM1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CKLF-CMTM1 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CKLF-CMTM1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CKLF-CMTM1 expression acts as an unfavorable survival marker.

LUSC and SARC are the cancer types where CKLF-CMTM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.133	0.776	<.001	24	view →
SARC	OS	Median	All	0.108	0.839	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CKLF-CMTM1–LUSC (OS)

Open the LUSC breakdown →